Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlotinib + carboplatin + cisplatin + pemetrexed
- Development stage
- Preclinical
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of anlotinib (a multi-target tyrosine kinase inhibitor that inhibits angiogenesis by targeting VEGFR, PDGFR, FGFR, and c-Kit), carboplatin (a platinum-based chemotherapy agent), cisplatin (a platinum-based chemotherapy agent), and pemetrexed (a folate analog that inhibits multiple enzymes involved in folate metabolism and DNA synthesis). This combination likely aims to leverage multiple mechanisms of action for enhanced anti-tumor efficacy in advanced cancers, particularly non-small cell lung cancer.
02
Targets
DNADHFR (Dihydrofolate reductase)EGFR (Epidermal growth factor receptor)GART (GAR transformylase)PDGFRB (Platelet-derived growth factor receptor beta)TS (Thymidylate synthase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)
Beyond the preview
Go deeper on anlotinib + carboplatin + cisplatin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlotinib + carboplatin + cisplatin + pemetrexed.